The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. (2018)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/ckj/sfy090
PubMed Identifier: 30524708
Publication URI: http://europepmc.org/abstract/MED/30524708
Type: Journal Article/Review
Volume: 11
Parent Publication: Clinical kidney journal
Issue: 6
ISSN: 2048-8505